|
[1]
|
American Psychiatric Association (APA) (2000). Diagnostic and statistical manual of mental disorders (4th ed.). Washington DC: American Psychiatric Association.
|
|
[2]
|
Abdelmawla, A. H., Langley, R. W., Szabadi, E., & Bradshaw, C. M. (1999). Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline and methoxamine-evoked constriction of the dorsal hand vein. British Journal of Clnical Pharmacology, 48, 345-354. http://dx.doi.org/10.1046/j.1365-2125.1999.00031.x
|
|
[3]
|
Ansseau, M., Papart, P., Troisfontaines, B., Bartholome, F., Bataille, M., Charles, G. et al. (1994). Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl), 114, 131-137. http://dx.doi.org/10.1007/BF02245454
|
|
[4]
|
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003). Depression and pain comorbidity: A literature review. Archives of Internal Medicine, 163, 2433-2445.
http://dx.doi.org/10.1001/archinte.163.20.2433
|
|
[5]
|
Bair, M. J., Robinson, R. L., Eckert, G. J., Stang, P. E., Croghan, T. W., & Kroenke, K. (2004). Impact of pain on depression treatment response in primary care. Psychosomatic Medicine, 66, 17-22.
http://dx.doi.org/10.1097/01.PSY.0000106883.94059.C5
|
|
[6]
|
Baldwin, D., Moreno, R. A., & Briley, M. (2008). Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology, 23, 527-532.
http://dx.doi.org/10.1002/hup.955
|
|
[7]
|
Benarroch, E. E. (2008). Descending monoaminergic pain modulation: Bidirectional control and clinical relevance. Neurology, 71, 217-221.
http://dx.doi.org/10.1212/01.wnl.0000318225.51122.63
|
|
[8]
|
Bradley, R. H., Barkin, R. L., Jerome, J., DeYoung, K., & Dodge, C. W. (2003) Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. American Journal of Therapeutics, 10, 318-323.
http://dx.doi.org/10.1097/00045391-200309000-00003
|
|
[9]
|
Brannan, S. K., Mallinckrodt, C. H., Brown, E. B., Wohlreich, M. M., Watkin, J. G., & Schatzberg, A. F. (2005). Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Journal of Psychiatric Research, 39, 43-53. http://dx.doi.org/10.1016/j.jpsychires.2004.04.011
|
|
[10]
|
Brecht, S., Courtecuisse, C., Debieuvre, C., Croenlein, J., Desaiah, D., Raskin, J. et al. (2007). Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: A randomized controlled trial. Journal of Clinical Psychiatry, 68, 1707-1716.
http://dx.doi.org/10.4088/JCP.v68n1110
|
|
[11]
|
Bymaster, F. P., Dreshfield-Ahmad, L. J., Threlkeld, P. G., Shaw, J. L., Thompson, L., Nelson, D. L. et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25, 871-880.
http://dx.doi.org/10.1016/S0893-133X(01)00298-6
|
|
[12]
|
Chang, T. T., Leng, C. H., Wu, J. Y., Lee, S. Y., Wang, Y. S., Chen, Y. C., Lu, R. B. et al. (2008). Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan. Chinese Journal of Physiology, 51, 387-393.
|
|
[13]
|
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R. et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet, 373, 746-758.
http://dx.doi.org/10.1016/S0140-6736(09)60046-5
|
|
[14]
|
Clauw, D. J., Mease, P., Palmer, R. H., Gendreau, R. M., & Wang, Y. (2008). Milnacipran for the treatment of fibromyalgia in adults: A 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clinical Therapeutics, 30, 1988-2004.
http://dx.doi.org/10.1016/j.clinthera.2008.11.009
|
|
[15]
|
Clerc, G. (2001). Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: A comparison with fluvoxamine. International Clinical Psychopharmacology, 16, 145-151.
http://dx.doi.org/10.1097/00004850-200105000-00003
|
|
[16]
|
Cymbalta (Package Insert) (2012). Indianapolis, Indiana: Eli Lilly and Company.
|
|
[17]
|
Danish University Antidepressant Group (1986). Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl), 90, 131-138.
|
|
[18]
|
Davidson, J., Watkins, L., Owens, M., Krulewicz, S., Connor, K., Carpenter, D. et al. (2005). Effects of paroxetine and venlafaxine XR on heart rate variability in depression. Journal of Clinical Psychopharmacology, 25, 480-484.
http://dx.doi.org/10.1097/01.jcp.0000177547.28961.03
|
|
[19]
|
Delgado, P. L., Brannan, S. K., Mallinckrodt, C. H., Tran, P. V., Mc-Namara, R. K., Wang, F. et al. (2005). Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. Journal of Clinical Psychiatry, 66, 686-692. http://dx.doi.org/10.4088/JCP.v66n0603
|
|
[20]
|
Delgado, P. L., Charney, D. S., Price, L. H., Aghajanian, G. K., Landis, H., & Heninger, G. R. (1990). Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry, 47, 411-418.
http://dx.doi.org/10.1001/archpsyc.1990.01810170011002
|
|
[21]
|
Delgado, P. L., Miller, H. L., Salomon, R. M., Licinio, J., Heninger, G. R., Gelenberg, A. J., Charney, D. S. et al. (1993). Monoamines and the mechanism of antidepressant action: Effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacology Bulletin, 29, 389-396.
|
|
[22]
|
Delgado, P. L., Moreno, F., Potter, R., & Gelenberg, A. J. (1997). Norepinephrine and serotonin in antidepressant action: Evidence from neurotransmitter depletion studies. In: M. Briley (Ed.), Antidepressant therapy at the dawn of the third millennium (pp. 141-163). London: Martin Dunitz, Ltd.
|
|
[23]
|
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002). Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Journal of Clinical Psychiatry, 63, 308-315.
http://dx.doi.org/10.4088/JCP.v63n0407
|
|
[24]
|
Detke, M. J., Lu, Y., Goldstein, D. J., McNamara, R. K., & Demitrack, M. A. (2002). Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. Journal of Psychiatric Research, 36, 383-390.
http://dx.doi.org/10.1016/S0022-3956(02)00060-2
|
|
[25]
|
DeVeaugh-Geiss, A. M., West, S. L., Miller, W. C., Sleath, B., Gaynes, B. N., & Kroenke, K. (2010). The adverse effects of comorbid pain on depression outcomes in primary care patients: Results from the ARTIST trial. Pain Medicine, 11, 732-741.
http://dx.doi.org/10.1111/j.1526-4637.2010.00830.x
|
|
[26]
|
Duenas, H., Brnabic, A. J., Lee, A., Montejo, A. L., Prakash, S., Casimiro-Querubin, M. L. et al. (2011). Treatment-emergent sexual dysfunction with SSRIs and duloxetine: Effectiveness and functional outcomes over a 6-month observational period. International Journal of Psychiatry in Clinical Practice, 15, 242-254.
http://dx.doi.org/10.3109/13651501.2011.590209
|
|
[27]
|
Effexor XR (Package Insert) (2012). Collegeville, PA: Wyeth Pharmaceuticals, Inc.
|
|
[28]
|
English, C., Rey, J. A., & Rufin, C. (2010). Milacipran (Savella), a treatment option for fibromyalgia. Drug Forecast, 35, 261-266.
|
|
[29]
|
Fava, M., Mallinckrodt, C. H., Detke, M. J., Watkin, J. G., & Wohlreich, M. M. (2004). The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates? Journal of Clinical Psychiatry, 65, 521-530. http://dx.doi.org/10.4088/JCP.v65n0411
|
|
[30]
|
Feighner, J. P. (1995). Cardiovascular safety in depressed patients: Focus on venlafaxine. Journal of Clinical Psychiatry, 56, 574-579.
|
|
[31]
|
Fields, H. L., Heinricher, M. M., & Mason, P. (1991). Neurotransmitters in nociceptive modulatory circuits. Annual Review of Neuroscience, 14, 219-245.
http://dx.doi.org/10.1146/annurev.ne.14.030191.001251
|
|
[32]
|
Goldstein, D. J., Lu, Y., Detke, M. J., Hudson, J., Iyengar, S., & Demitrack, M. A. (2004). Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics, 45, 17-28.
http://dx.doi.org/10.1176/appi.psy.45.1.17
|
|
[33]
|
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002). Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial. Journal of Clinical Psychiatry, 63, 225-231.
http://dx.doi.org/10.4088/JCP.v63n0309
|
|
[34]
|
Greco, T., Eckert, G., & Kroenke, K. (2004). The outcome of physical symptoms with treatment of depression. Journal of General Internal Medicine, 19, 813-818.
http://dx.doi.org/10.1111/j.1525-1497.2004.30531.x
|
|
[35]
|
Guelfi, J. D., Ansseau, M., Corruble, E., Samuelian, J. C., Tonelli, I., Tournoux, A., Plétan, Y. et al. (1998). A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. International Clinical Psychopharmacology, 13, 121-128.
http://dx.doi.org/10.1097/00004850-199805000-00005
|
|
[36]
|
Hudson, J. I., Wohlreich, M. M., Kajdasz, D. K., Mallinckrodt, C. H., Watkin, J. G., & Martynov, O. V. (2005). Safety and tolerability of duloxetine in the treatment of major depressive disorder: Analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharmacology, 20, 327-341.
http://dx.doi.org/10.1002/hup.696
|
|
[37]
|
Ibor, J. J., Carrasco, J. L., Prieto, R., & Garcia-Calvo, C. (2008). Effectiveness and safety of venlafaxine extended release in elderly depressed patients. Archives of Gerontology and Geriatrics, 46, 317-326.
http://dx.doi.org/10.1016/j.archger.2007.05.005
|
|
[38]
|
Iyengar, S., Webster, A. A., Hemrick-Luecke, S. K., Xu, J. Y., & Simmons, R. M. A. (2004). Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. Journal of Pharmacological Experimental Therapeutics, 311, 576-584. http://dx.doi.org/10.1124/jpet.104.070656
|
|
[39]
|
Kelin, K., Berk, M., Spann, M., Sagman, D., Raskin, J., Walker, D., & Perahia, D. (2010). Duloxetine 60 mg/day for the prevention of depressive recurrences: Post hoc analyses from a recurrence prevention study. International Journal of Clinical Practice, 64, 719-726.
http://dx.doi.org/10.1111/j.1742-1241.2010.02374.x
|
|
[40]
|
Kihara, T., & Ikeda, M. (1995). Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. Journal of Pharmacology and Experimental Therapeutics, 272, 177-183.
|
|
[41]
|
Knadler, M. P., Lobo, E., Chappell, J., & Bergstrom, R. (2011). Duloxetine: Clinical pharmacokinetics and drug interactions. Clinical Pharmacokinetics, 50, 281-294.
http://dx.doi.org/10.2165/11539240-000000000-00000
|
|
[42]
|
Koch, S., Hemrick-Luecke, S. K., Thompson, L. K., Evans, D. C., Threlkeld, P. G., Nelson, D. L., Perry, K. W., & Bymaster, F. P. (2003). Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology, 45, 935-944. http://dx.doi.org/10.1016/S0028-3908(03)00268-5
|
|
[43]
|
Koch, S., Perry, K. W., Nelson, D. L., Conway, R. G., Threlkeld, P. G., & Bymaster, F. P. (2001). R-Fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: An in Vivo microdialysis and receptor binding study. Neuropsychopharmacology, 27, 949-959.
http://dx.doi.org/10.1016/S0893-133X(02)00377-9
|
|
[44]
|
Kornstein, S. G. (2008). Maintenance therapy to prevent recurrence of depression: Summary and implications of the PREVENT study. Expert Review of Neurotherapeutics, 8, 737-742.
http://dx.doi.org/10.1586/14737175.8.5.737
|
|
[45]
|
Lecrubier, Y., Pletan, Y., Solles, A., Tournoux, A., & Magne, V. (1996). Clinical efficacy of milnacipran: Placebo-controlled trials. International Clinical Psychopharmacology, 11, 29-33.
http://dx.doi.org/10.1097/00004850-199609004-00004
|
|
[46]
|
Lee, K. U., Lee, Y. M., Nam, J. M., Lee, H. K., Kweon, Y. S., Lee, C. T., & Jun, T. Y. (2010). Antidepressant-Induced sexual dysfunction among newer antidepressants in a naturalistic setting. Psychiatry Investigation, 7, 55-59.
http://dx.doi.org/10.4306/pi.2010.7.1.55
|
|
[47]
|
Lee, M. S., Ahn, Y. M., Chung, S., Walton, R., Raskin, J., & Kim, M. S. (2012). The effect of initial duloxetine dosing strategy on nausea in korean patients with major depressive disorder. Psychiatry Investigation, 9, 391-399. http://dx.doi.org/10.4306/pi.2012.9.4.391
|
|
[48]
|
Lee, M. S., Ham, B. J., Kee, B. S., Kim, J. B., Yeon, B. K., Oh, K. S., Ohg, B. H., Leeh, C., Jungi, H. Y., Cheej, I.S., Choek, B. M., & Paik, I. H. (2005). Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Current Medical Research & Opinion, 21, 1369-1375.
http://dx.doi.org/10.1185/030079905X59166
|
|
[49]
|
Lenox-Smith, A., D’yachkova, Y., Deberdt, W., & Raskin, J. (2010). Meta-Analyses and antidepressant prescribing. Journal of Psychopharmacology, 24, 629-630.
http://dx.doi.org/10.1177/0269881110364440
|
|
[50]
|
Lenox-Smith, A., Kelin, K., Brnabic, A. J., & Bradley, A. (2011). efficacy of Duloxetine vs Venlafaxine—An updated non-inferiority analysis in major depressive disorder. In 11th International Forum on Mood and Anxiety Disorders (IFMAD), Budapest, 9-11 November, 2011. International Journal of Psychiatry in Clinical Practice, 15, 30.
|
|
[51]
|
Leuchter, A. F., Husain, M. M., Cook, I. A., Trivedi, M. H., Wisniewski, S. R., Gilmer, W. S., Luthera, J. F., Favaa, M., & Rush, A. J. (2010). Painful physical symptoms and treatment outcome in major depressive disorder: A STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychological Medicine, 40, 239-251.
http://dx.doi.org/10.1017/S0033291709006035
|
|
[52]
|
Lobello, K. W., Preskorn, S. H., Guico-Pabia, C. J., Jiang, Q., Paul, J., Nichols, A. I., Patroneva, A., & Ninan, P. T. (2010). Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: A secondary analysis of 4 studies in major depressive disorder. Journal of Clinical Psychiatry, 71, 1482-1487.
http://dx.doi.org/10.4088/JCP.08m04773blu
|
|
[53]
|
Lobo, E. D., Bergstrom, R. F., Reddy, S., Quinlan, T., Chappell, J., Hong, Q., Ring, B., & Knadler, M. P. (2008). In Vitro and in Vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clinical Pharmacokinetics, 47, 191-202.
http://dx.doi.org/10.2165/00003088-200847030-00005
|
|
[54]
|
Maletic, V., & Raison, C. L. (2009). Neurobiology of depression, fibromyalgia and neuropathic pain. Frontiers in Bioscience, 14, 5291-5338. http://dx.doi.org/10.2741/3598
|
|
[55]
|
Mallinckrodt, C. H., Goldstein, D. J., Detke, M. J., Lu, Y., Watkin, J. G., & Tran, P. V. (2003). Duloxetine: A new treatment for the emotional and physical symptoms of depression. Primary Care Companion to the Journal of Clinical Psychiatry, 5, 19-28.
http://dx.doi.org/10.4088/PCC.v05n0105
|
|
[56]
|
Mease, P. J., Clauw, D. J., Gendreau, R. M., Rao, S. G., Kranzler, J., Chen, W., & Palmer, R. H. (2009). The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. Journal of Rheumatology, 36, 398-409.
http://dx.doi.org/10.3899/jrheum.080734
|
|
[57]
|
Nakagawa, A., Watanabe, N., Omori, I. M., Barbui, C., Cipriani, A., McGuire, H., Churchill, R., & Furukawa, T. A. (2008). Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: A systematic review and meta-analysis. CNS Drugs, 22, 587-602.
http://dx.doi.org/10.2165/00023210-200822070-00004
|
|
[58]
|
Nelson, J. C., Mazure, C. M., Jatlow, P. I., Bowers Jr., M. B., & Price, L. H. (2004). Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: A double-blind, randomized study. Biological Psychiatry, 55, 296-300.
http://dx.doi.org/10.1016/j.biopsych.2003.08.007
|
|
[59]
|
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D. M., & Thase, M. E. (2008). Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry, 63, 424-434. http://dx.doi.org/10.1016/j.biopsych.2007.06.027
|
|
[60]
|
Nemeroff, C. B., Schatzberg, A. F., Goldstein, D. J., Detke, M. J., Mallinckrodt, C., Lu, Y., & Tran, P. V. (2002). Duloxetine for the treat0 ment of major depressive disorder. Psychopharmacology Bulletin, 36, 106-132.
|
|
[61]
|
Nemeroff, C. B., & Thase, M. E. (2007). A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Journal of Psychiatric Research, 41, 351-359.
http://dx.doi.org/10.1016/j.jpsychires.2005.07.009
|
|
[62]
|
Nierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., & Wohlreich, M. M. (2007). Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, a non-inferiority study. Current Medical Research & Opinion, 23, 401-416.
http://dx.doi.org/10.1185/030079906X167453
|
|
[63]
|
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? a meta-analysis of studies of newer agents. Biological Psychiatry, 62, 1217-1227.
http://dx.doi.org/10.1016/j.biopsych.2007.03.027
|
|
[64]
|
Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a con0 trolled multicenter study. Danish University Antidepressant Group. (1990). Journal of Affective Disorders, 18, 289-299.
|
|
[65]
|
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006). Duloxetine in the prevention of relapse of major depressive disorder: Double-blind placebo-controlled study. British Journal of Psychiatry, 188, 346-353.
http://dx.doi.org/10.1192/bjp.188.4.346
|
|
[66]
|
Perahia, D. G., Kajdasz, D. K., Desaiah, D., & Haddad, P. M. (2005). Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of Affective Disorders, 89, 207-212.
http://dx.doi.org/10.1016/j.jad.2005.09.003
|
|
[67]
|
Perahia, D. G., Maina, G., Thase, M. E., Spann, M. E., Wang, F., Walker, D. J., & Detke, M. J. (2009). Duloxetine in the prevention of depressive recurrences: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 70, 706-716.
http://dx.doi.org/10.4088/JCP.08m04756
|
|
[68]
|
Perahia, D. G., Pritchett, Y. L., Kajdasz, D. K., Bauer, M., Jain, R., Russell, J. M., Walker, D. J., Spencer, K. A., Froud, D. M., Raskin, J., & Thase, M. E. (2008a). A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Journal of Psychiatric Research, 42, 22-34.
http://dx.doi.org/10.1016/j.jpsychires.2007.01.008
|
|
[69]
|
Perahia, D. G., Quail, D., Desaiah, D., Corruble, E., & Fava, M. (2008b). Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: A multicenter trial comparing 2 switching techniques. Journal of Clinical Psychiatry, 69, 95-105.
http://dx.doi.org/10.4088/JCP.v69n0113
|
|
[70]
|
Plesnicar, B. K. (2010). Efficacy and tolerability of venlafaxine extended release in patients with major depressive disorder. Psychiatria Danubina, 22, 413-417.
|
|
[71]
|
Puech, A., Montgomery, S. A., Prost, J. F., Solles, A., & Briley, M. (1997). Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. International Clinical Psychopharmacology, 12, 99-108.
http://dx.doi.org/10.1097/00004850-199703000-00005
|
|
[72]
|
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial. American Journal of Psychiatry, 164, 900-909.
http://dx.doi.org/10.1176/appi.ajp.164.6.900
|
|
[73]
|
Rouillon, F., Berdeaux, G., Bisserbe, J. C., Warner, B., Mesbah, M., Smadja, C., & Chwalow, J. (2000a). Prevention of recurrent depresssive episodes with milnacipran: Consequences on quality of life. Journal of Affective Disorders, 58, 171-180.
http://dx.doi.org/10.1016/S0165-0327(99)00109-3
|
|
[74]
|
Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C. (2000b). Milnacipran efficacy in the prevention of recurrent depression: A 12-month placebo-controlled study. Milnacipran recurrence prevention study group. International Clinical Psychopharmacology, 15, 133-140. http://dx.doi.org/10.1097/00004850-200015030-00002
|
|
[75]
|
Rudolph, R. L., & Derivan, A. T. (1996). The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database. Journal of Clinical Psychopharmacolology, 16, 54S-59S.
http://dx.doi.org/10.1097/00004714-199606002-00011
|
|
[76]
|
Rudolph, R. L., Fabre, L. F., Feighner, J. P., Rickels, K., Entsuah, R., & Derivan, A. T. (1998). A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. Journal of Clinical Psychiatry, 59, 116-122.
http://dx.doi.org/10.4088/JCP.v59n0305
|
|
[77]
|
Savella (package insert) (2012). New York: Forest Laboratories, Inc.
|
|
[78]
|
Schatzberg, A., & Roose, S. (2006). A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. American Journal of Geriatric Psychiatry, 14, 361-370.
http://dx.doi.org/10.1097/01.JGP.0000194645.70869.3b
|
|
[79]
|
Schweitzer, I., Maguire, K., & Ng, C. (2009). Sexual side-effects of contemporary antidepressants: Review. Australian and New Zealand Journal of Psychiatry, 43, 795-808.
http://dx.doi.org/10.1080/00048670903107575
|
|
[80]
|
Sechter, D., Vandel, P., Weiller, E., Pezous, N., Cabanac, F., & Tournoux, A. (2004). A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of Affective Disorders, 83, 233-236. http://dx.doi.org/10.1016/j.jad.2004.07.002
|
|
[81]
|
Shelton, C., Entsuah, R., Padmanabhan, S. K., & Vinall, P. E. (2005). Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. International Clinical Psychopharmacology, 20, 233-238.
http://dx.doi.org/10.1097/00004850-200507000-00007
|
|
[82]
|
Shelton, R. C., Andorn, A. C., Mallinckrodt, C. H., Wohlreich, M. M., Raskin, J., Watkin, J. G., & Detke, M. J. (2007). Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression. International Clinical Psychopharmacology, 22, 348-355.
http://dx.doi.org/10.1097/YIC.0b013e32821c6189
|
|
[83]
|
Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002). Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. British Journal of Psychiatry, 180, 396-404.
http://dx.doi.org/10.1192/bjp.180.5.396
|
|
[84]
|
Stahl, S. M. (2002). Does depression hurt? Journal of Clinical Psychiatry, 63, 273-274.
http://dx.doi.org/10.4088/JCP.v63n0401
|
|
[85]
|
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology, 340, 249-258.
http://dx.doi.org/10.1016/S0014-2999(97)01393-9
|
|
[86]
|
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001). Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. British Journal of Psychiatry, 178, 234-241.
http://dx.doi.org/10.1192/bjp.178.3.234
|
|
[87]
|
Thase, M. E., Pritchett, Y. L., Ossanna, M. J., Swindle, R. W., Xu, J., & Detke, M. J. (2007). Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder. Journal of Clinical Psychopharmacology, 27, 672-676.
http://dx.doi.org/10.1097/jcp.0b013e31815a4412
|
|
[88]
|
Thase, M. E., Tran, P. V., Wiltse, C., Pangallo, B. A., Mallinckrodt, C., & Detke, M. J. (2005). Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. Journal of Clinical Psychopharmacology, 25, 132-140.
http://dx.doi.org/10.1097/01.jcp.0000155815.44338.95
|
|
[89]
|
Trivedi, M. H. (2004). The link between depression and physical symptoms. Primary Care Companion to the Journal of Clinical Psychiatry, 6, 12-16.
|
|
[90]
|
Wohlreich, M. M., Martinez, J. M., Mallinckrodt, C. H., Prakash, A., Watkin, J. G., & Fava, M. (2005). An open-label study of duloxetine for the treatment of major depressive disorder: Comparison of switching versus initiating treatment approaches. Journal of Clinical Psychopharmacology, 25, 552-560.
http://dx.doi.org/10.1097/01.jcp.0000185429.10053.c8
|
|
[91]
|
Wong, D. T., & Bymaster, F. P. (2002). Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Progress in Drug Research, 58, 169-222.
http://dx.doi.org/10.1007/978-3-0348-8183-8_5
|
|
[92]
|
Zanger, U. M., Raimundo, S., & Eichelbaum, M. (2004). Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Archives of Pharmacology, 369, 23-37. http://dx.doi.org/10.1007/s00210-003-0832-2
|